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Mesenchymal stem cells (MSCs) are an alluring therapeutic resource because of their plasticity, immunoregulatory capacity and
ease of availability. Human BM-derived MSCs have limited proliferative capability, consequently, it is challenging to use in tissue
engineering and regenerative medicine applications. Hence, placental MSCs of maternal origin, which is one of richest sources
of MSCs were chosen to establish long-term culture from the cotyledons of full-term human placenta. Flow analysis established
bonaﬁed MSCs phenotypic characteristics, staining positively for CD29, CD73, CD90, CD105 and negatively for CD14, CD34,
CD45 markers. Pluripotency of the cultured MSCs was assessed by in vitro diﬀerentiation towards not only intralineage cells
like adipocytes, osteocytes, chondrocytes, and myotubules cells but also translineage diﬀerentiated towards pancreatic progenitor
cells, neural cells, and retinal cells displaying plasticity. These cells did not signiﬁcantly alter cell cycle or apoptosis pattern while
maintaining the normal karyotype; they also have limited expression of MHC-II antigens and are Naive for stimulatory factors
CD80 and CD 86. Further soft agar assays revealed that placental MSCs do not have the ability to form invasive colonies.
Taking together all these characteristics into consideration, it indicates that placental MSCs could serve as good candidates for
development and progress of stem-cell based therapeutics.
1.Introduction
The term Mesenchymal stem cells (MSCs) was coined
by Caplan in 1991 [1]. MSCs are deﬁned as the class
of stem cells that has the potential to self-renew and
diﬀerentiate into multiple cell lineages [2, 3]. The pres-
ence of mesenchymal stem cells in the bone marrow was
hypothesized by Cohnheim in 1860s [4]. In 1920s, Maximow
postulated the importance of the marrow stromal tissue in
supporting the development and maintenance of blood and
hematopoieticorgans[5].In1960s,Friedensteinwastheﬁrst
to demonstrate stromal cells could be isolated from whole
bone marrow aspirate based on diﬀerentiation adhesion to
tissue culture plastic dishes [6]. In addition, MSCs secrete
proangiogenic [7] and antiapoptotic cytokines and possess
immunosuppressive properties [8]. Bone marrow MSCs are
most commonly used and primary source of MSCs [9].
However, due to invasive nature of bone marrow aspiration
and limited proliferative capacity, eﬀorts are underway to
identify abundant and reliable sources of MSCs for clinical
applications [9]. Mesenchymal stem cells can be broadly
grouped into two diﬀerent subgroups adult MSCs and
fetal MSCs. Adult MSCs are isolated from bone marrow,
peripheral blood. Fetal MSCs are isolated from Placenta,
amnioticﬂuid,umbilicalcordandumbilicalcordblood[10].
Placenta provides one of the most reliable and abundant
source of MSCs [11]. Term placental tissues are discarded
after birth, hence these tissues can be eﬀectively utilized for
research as well as clinical application without much ethical
concern. In this paper, we systematically characterize the
term placental MSCs isolated from cotyledons and validated
that the isolated MSCs fulﬁll the genotypic and functional2 Stem Cells International
criteria laid out for a proper MSC [11, 12]. We have
demonstrated that these MSCs have the ability to rapidly
expand up to even 25–30 passages without compromising
the chromosomal number, cell cycle or apoptosis pattern,
phenotypic characteristics, pluripotency-associated endoge-
nous gene expression proﬁle, and diﬀerentiation capacity.
Placental MSCs were able to transdiﬀerentiate into other cell
lineages thus exhibiting their inherent plasticity.
2.MaterialsandMethods
2.1. Collection of the Human Placenta Samples. The ethical
committee of Christian Medical College (CMC), Vellore,
approved the study. Following the written consent term
placental samples were collected from donors after elective
caesarean.
2.2. Cell Isolation. Term human placental MSCs were iso-
lated from cotyledons present towards the maternal side of
the placenta. The placental membrane from the maternal
side of the placenta was cut open and about 80g of
cotyledons was exercised. The cotyledons was thoroughly
washed with PBS and cut into small pieces. The blood clots
present in the cotyledons were mechanically removed. The
minced placental was once again washed with physiological
saline and subjected to sequential digestion with trypsin
and collagenase I. The tissues were incubated with 0.25%
trypsinfor1hourat37 ◦C.Aftertrypsindigestion,thesample
was ﬁltered through 250μm metal sieve. The retentate was
collected and subjected to second digestion with12.5 U/mL
c o l l a g e n a s eIf o r1h o u ra t3 7 ◦C. Collagenase I digested tissue
sample was passed ﬁrst through 250μmm e t a ls i e v ea n d
ﬁltratecollectedwaspassedthrough100μmcellstrainer.The
ﬁltrate containing cell suspension after dual ﬁltration stages
were subjected to centrifugation at 300g for 10 minutes.
The cell pellet was resuspended in RBC lysis buﬀer and
centrifugedat300gfor10minutes.Finally,thecellpelletwas
resuspended in Mesenchymal expansion medium (αMEM +
10% FBS + 50u/mL penicillin + 50μg/mL streptomycin +
1mM L-glutamine) and plated into two 75cm2 ﬂasks.
2.3. Antibodies. Information on primary and secondary
antibodies used for ﬂow-cytometry and immunostaining
experiments is provided in Supplementary Table 1 is avail-
able online at doi: 10.1155/2012/174328.
2.4. Flow Cytometry. Cells after trypsinization was equally
aliquoted (1 × 105 cells per reaction) into FACS tubes and
stained on live cells with respective antibody. Unstained
antibody and cells stained with isotype antibody acted as
controls. Antibodies were added to the cells in dark to avoid
bleaching. After addition of the antibody, the sample was
incubated at room temperature in dark for 20 minutes.
Cells were washed with 1mL of DPBS without calcium
and magnesium and centrifuged at 300g for 5min. The
pelleted cells were resuspended in 300μL DPBS w/o calcium
and magnesium and analyzed with a ﬂow cytometer (FACS
Calibur; Becton Dickinson). A minimum of 104 gated events
was acquired from each sample for analysis using cell
quest.
2.5. Cytogenetic Analysis. Karyotyping of human placental
MSCs was carried at Passages 5 and 25 to verify the chro-
mosomal integrity. Metaphase chromosomal preparations
were performed according to standard procedures at a 400–
550 GTG band level. Zeiss axioplan microscope was used to
identifyandanalysethechromosomes.Imageswereanalyzed
with a photometrics charged coupled device camera and
controlled with smart capture imaging software.
2.6. Immunostaining. The cells cultured in 6-well plates were
blocked with PBS (without Ca2+ and Mg2+) containing 0.1%
BSA, ﬁxed with 4% paraformaldehyde and permeabilized
using 0.2% Triton X-100. If using unconjugated antibody,
samples were ﬁrst incubated with primary antibody, blocked
with PBS containing 0.1% BSA and subsequently incubated
with ﬂuorescent dye conjugated secondary antibody. All
cell samples were additionally counterstained with Hoechst
33342. Images were taken using leica DMI6000B (Leica)
equipped with DFC360FX digital camera and analyzed with
Lecia AF imaging software (Leica).
2.7. Total RNA Isolation and Reverse Transcription Polymerase
Chain Reaction (RT-PCR). Total RNA isolation was carried
out using Trizol (Invitrogen). cDNA was prepared with
superscript III reverse transcriptase enzyme. The primer
sequences and their respective annealing temperature are
presented in supplementary entary Table 2. PCR conditions
were initial denaturation at 94◦C for 2min, followed by
denaturation at 94◦C for 1min, annealing for 1min, exten-
sion at 72◦C for 2min for 35 cycles, and ﬁnal extension was
carried out at 72◦C for 5min. Glyceraldehyde 3 phosphate
dehydrogenase (GAPDH) RNA was used as a control for
normalization of RNAs. PCR products were analyzed using
ethidium bromide stained 2% agarose gels. Analysis of the
gel images was carried out (Supplementary Table 2).
2.8.QPCR. TotalRNAwasextractedwithTrizol(Invitrogen)
according to the manufacturer’s protocol. cDNA synthesis
was carried out using Superscript III First-Strand synthesis
system (Invitrogen). qRT-PCRs were carried out with SYBR
Green master mix and AB real-time thermocycler (AB 7500).
Primer sequences for the analysis of endogenous pluripo-
tency gene expression are mentioned in the table below. The
expression levels of individual genes were normalized against
β-Actin (Supplementary Table 2).
2.9. Cell Cycle Analysis. For cell cycle analysis [13], cells were
ﬁxed with cold methanol, treated with RNase A 10μg/mL,
stained with Propidium Iodide 50μg/mL, and analyzed by
ﬂowcytometer.Stem Cells International 3
2.10. Apoptosis Analysis. Apoptosis analysis was carried by
following the manufacturer’s instructions (BD Pharmingen
Annexin V). The cells were subjected to live staining with
Annexin V and 7-AAD and analyzed the cells through
ﬂowcytometer.
2.11. Oligo-Lineage Diﬀerentiation Analysis. Placental MSCs
at various passages were subjected intra- and translineage
diﬀerentiation protocol to analyze the plasticity of the cells.
After diﬀerentiation, cells were stained with appropriate
stains and examined microscopically under Leica micro-
scope.
2.12. Adipogenic Diﬀerentiation. Placental MSCs at 5 × 104
cells were seeded onto 24-well plate (corning) containing
adipogenic diﬀerentiation medium (Invitrogen) for 30 days,
fresh medium added every 48 hours. Oil red O staining was
carriedouttovisualizethepresenceoffatdroplets.Cellswere
ﬁxed with 4% paraformaldehyde, washed with sterile water,
and incubated with 60% isopropanol at room temperature.
Fixed cells were stained with 0.5% oil red O in isopropanol
for20minutesatroomtemperature.Afterstaining,cellswere
ﬁrst washed with 60% isopropanol later rinsed with sterile
water before observing under the microscope for imaging.
2.13. Chondrogenic Diﬀerentiation. Chondrogenic diﬀeren-
tiation was carried out using falcon25 static cell culture
system (specially fabricated in our lab for chondrocyte
diﬀerentiation). Cells were subjected to micromass cell
culture conditions to induce the chondrocyte diﬀerentiation
under chondrocyte diﬀerentiation medium (Invitrogen) for
30 days. One million MSCs were pelleted at 300g and
chondrocyte diﬀerentiation medium was added without
disturbing the pellet. Media was changed every 48hrs. After
diﬀerentiation, cells were ﬁxed with 10% formalin, stained
with merchrome, and embedded in paraﬃn. Staining on
deparaﬃnized 5μm sections staining for proteoglycans was
carried out using saﬀranin O and 3% alcian blue. After
staining, sections were rinsed with distilled water, air dried at
room temperature, immersed in xylene, and mounted using
DPX before observing under microscopy.
2.14. Osteogenic Diﬀerentiation. For osteogenic diﬀerentia-
tion, 5 × 104 cells were seeded per well in 24-well plate
containing osteogenic induction medium (Invitrogen) for 30
days, with media change every 48hrs. After diﬀerentiation,
presenceofextracellularcalciumwasconﬁrmedbyVonKossa
staining. For vonkossa staining, the cells were ﬁxed in pre-
cooled methanol. After ﬁxing, the cells were washed with
DPBS (W/O Ca2+ and Mg2+), treated with 5% silver nitrate
solution in water, and exposed to UV light for 1 hour under
the laminar hood. Stained cells were washed with water and
incubated with 5% sodium thiosulphate in water for 2min
at room temperature. Finally, sample was rinsed with sterile
water and observed under the microscope for imaging.
2.15. Myotubule Diﬀerentiation. For myotubule diﬀerentia-
tion[14],5 ×104 placentalMSCswereseededin25cm2 ﬂask
containing mesenchymal expansion medium with 3μM5 -
azacytidine. The cells were cultured for 21 days with media
changes every 7 days. The cells were stained with Hoechst
33342 (5μg/mL), incubated at 37◦C for 30 minutes before
observing under the microscope for imaging.
2.16. Tubular Assay. Matrigel (BD) was thawed at 4◦Cf o r
overnight. 50μL of matrigel was aliquoted per well of 96 well
plate using precooled tips. The plate was centrifuged at 300g
for 5min, 4◦C. Allowed to polymerize at 37◦C for 30min.
MSCs at 1 × 105 cells/well were seeded in mesenchymal
expansion medium. Cells were incubated at 37◦Cu n d e r
hypoxic condition for 6 hours before observing under the
microscope for imaging [15].
2.17. Neural Diﬀerentiation. To induced neuronal diﬀeren-
tiation [16], 5 × 105 placental MSCs were seeded onto
serum-free α-MEM containing 5mM β-mercaptoethanol
a n dc u l t u r e df o r6 – 9h r s .T h ec e l l sa f t e ri n d u c t i o nw e r eﬁ x e d
for immunostaining analysis.
2.18. Retinal Cell Diﬀerentiation. For Retinal diﬀerentiation
[17], 1 × 105 cells were seeded into media containing
Mesenchymal expansion medium supplemented with 50μM
Taurine with 1mM Beta-mercaptoethanol. The cells, were
cultured for 4 days with media changes every 4 days. After
retinal induction cells were collected in trizol for RT-PCR
analysis or ﬁxed for immunostaining.
2.19. Pancreatic Progenitor Cell Diﬀerentiation. For pancre-
atic diﬀerentiation [12, 18, 19], 25cm2 ﬂasks were treated
with gelatin and 5 × 105 cells were seeded onto gela-
tinized dish containing mesenchymal expansion medium
with 10mM nicotinamide and 1mM β-Mercaptoethanol
for 24hrs. Following preinduction, cells were treated with
Mesenchymal expansion medium without FBS but contain-
ing 10mM nicotinamide and 1mM β-Mercaptoethanol for
6 hours, and for following 18hrs cells were treated with
induction media containing FBS. After diﬀerentiation, cells
were collected in trizol and subjected to RT-PCR analysis or
ﬁxed for immunostaining.
2.20. Soft Agar Assay. For Soft agar assay [20], 0.6% agar
containing MEM was layered on the surface of 35mm dish
(corning) and incubated in laminar hood for 30min. Later, 2
× 104 MSCs were mixed with 0.3% agar containing MEM
and overlayed on the top of 0.6% agar layer. Plate was
incubated in hood for 20 minutes. Following incubation,
500μL of Mesenchymal expansion medium was added and
incubated for 21 days. To the dish, 500μL of fresh media was
a d d e de v e r y7d a y so n c e .H e L ac e l l sw e r eu s e da sap o s i t i v e
control.
2.21. Dithizone Staining. For Dithizone (STZ) Staining, the
cells were incubated with DTZ solution 100μg/mL in α-
MEM media for 20 minutes at 37◦C. After staining, the4 Stem Cells International
cells were rinsed with twice with PBS and examined under
microscope [21].
2.22. Cell Population Doubling Time (Gt). Population dou-
bling time indicates the growth rate of the placental MSCs
[22], population doubling (PD)
PD =
ln(Nf/Ni)
ln2
,( 1 )
where ln equals natural logarithm, Nf equals ﬁnal cell count,
Ni equals initial cell count
Gt =
t
PD
,( 2 )
t = Time in hours after cell seeding.
Average Gt value was attained by adding the obtained
Gt values for diﬀerent experiments divided by number of
experiments.
3. Results
3.1. Derivation of Adherent Fibroblast Like Mesenchymal
Stem Cells (MSCs) from Maternal Side of Human Placenta
and Immunophenotypic Characterization of Human Placental
MSCs. Enzyme-mediated fractionation of human termed
placenta resulted in derivation of ﬁbroblast-like cells, which
are generally term placenta-derived multipotent mesenchy-
mal stem cells (PD-MSCs). Selection for MSCs rested on the
classic adhesion method on tissue culture plastic. Placental
MSCs from 8 term placental samples have been established
from maternal side lobules of human placenta following
trypsin digestion and collagenase-I treatment following
which samples were passed through the 100μ ﬁlter and were
seeded in α-MEM containing 10% FBS, and adherent cell
population was then characterized for their proliferation
capabilities,cellcycle,apoptosispattern,immunophenotypic
features, and diﬀerentiation capabilities. The isolated MSCs
formed a homogenous monolayer of adherent spindle-
shapedﬁbroblast-likecells.Theprotocolprovedsuccessfulin
8 of 8 placental tissues collection. Plating of cell suspensions
from the ﬁrst digest with trypsin did not produce any
colonies, but cell suspensions produced from ﬁnal collage-
nase I digest of placental tissue fragments typically produced
MSC colonies of variable sizes that contained outgrowing
ﬁbroblast-like cells. After initial plating of the cells, the
colonies became visible after 7 days. These MSC colonies in
turn started to proliferate steadily, the ﬂask was almost 60–
70% conﬂuent and ready for splitting by day 14. Typically,
approximately 5–6 × 104 cells were obtained within 12–
14 days after plating. Following the process of initiation
the ﬂasks were subjected to trypsinization in 1:2 or 1:3
ratio. The 75cm2 at 1:2 splitting was subconﬂuent by day
3, indicating these isolated cells had very rapid proliferating
capacity. Outgrowing cells when harvested and replated in
higherdilutionsrapidlyformedsecondarycoloniesfromsin-
gle cells (Figures 1(a) and 1(b)) .P D - M S C sw e r ee x p a n d a b l e
up to passage 25–30 (as far as we cultured) without any
changes in the morphological characteristics (Figures 1(c)
and 1(d)) and were amenable to routine cryopreservation,
thawing and diﬀerentiation protocols. The MSCs were
characterized using ﬂow-cytometry-based positive reaction
for mesenchymal lineage surface markers CD29+, CD73+,
CD90+, CD105+; and negative for hematopoietic marker
CD34−, CD45−, also negative expression of CD14−,H L A
DR−; was used to deﬁne MSCs (Figures 1(c), 1(d),a n d1(e)).
Flow cytometry revealed very little scatter in the phenotypic
marker proﬁle of placenta-derived isolates between all 8
cases, also population doubling time calculated were not
signiﬁcantly altered. The expression proﬁle conﬁrmed to the
criteria generally deﬁned for multipotent mesenchymal stem
cells [23].
3.2. Plasticity of MSCs. Speciﬁc induction of diﬀerentiation
was investigated with PD-MSCs, one early, one mid, and one
late passage from all 8 subjects. This conﬁrmed that the mes-
enchymal stemness proﬁle by PD-MSC populations indeed
associated with the ability to generate diﬀerent mesodermal
lineage cell types on their exposure to soluble growth and
diﬀerentiation factors in vitro. At the same time, when sub-
jected to translineage diﬀerentiation MSC shows remarkable
plasticity to diﬀerentiate into ectodermal (neuronal cells,
retinal cells) and endodermal lineage (pancreatic beta cells).
Subconﬂuentculturewasfoundcriticallyimportanttomain-
tain the stemness phenotype of PD-MSCs during expansion.
The phenotypic proﬁle of PD-MSCs when subcultured at
50–70% cell density remained unaﬀected, also maintained
their initial marker proﬁle and their ability to diﬀerentiate
as well. MSCs can be diﬀerentiated into cells from all the
threegermlayersundersuitablesupplementaryconditionsin
vitro. The ﬁgures display representative results of adipogenic
(Figure 2 (a)), osteogenic (Figure 2 (b)), and chondrogenic
(Figures 2 (c),a n d2( d ) )d i ﬀerentiation assays, visualizing
large lipid vacuoles, mineralized bone with calcium deposits
and saﬀranin O positive collagen matrix respectively. These
adipogenesis, osteogenesis, and chondrogenesis along with
myotubule formation (Figure 2 (e)) and endothelial cells
tubular assay (Figure 2 (f)) indicates the ability of the MSC
to diﬀerentiate into mesodermal cell lineage. Moreover,
reports are available on MSC culture in presence of the
angiogenicgrowthfactorVEGFinducedexpressionofCD34,
which is a marker of hematopoietic, as well as endothelial,
precursors [35]. Figure also shows neurogenesis (Figures 2
(g), 2( h ) , 2( i ) , 2( j ) ,a n d2( k ) ) and retinal cell (Figure 2 (l))
diﬀerentiation which exhibits the ectodermal diﬀerentiation
capacity of MSCs. Further, diﬀerentiation in pancreatic beta
cells indicates (Figure 2 (m)) the endodermal diﬀerentiation
capacity of placental MSCs. Also, RT-PCR ampliﬁcation of
calbindin2 and recoverin genes shows (Figure 2 (n)) retinal
(ectodermal lineage) diﬀerentiation, and pancreatic amylase
gene (Figure 2 (n)) was also ampliﬁed after pancreatic beta
cell induction.
3.3. Extensively Passaged Placenta-Derived MSC Does Not
Signiﬁcantly Alter the Cell Cycle or Apoptotic Pattern While
Maintaining the Normal Karyotype. In the next set ofStem Cells International 5
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Figure 1: Morphology and characteristics of placental MSCs. (a) morphology of the placental MSCs at passage 5; (b) morphology of the
placental MSCs at passage 25; (c) ﬂowcytometric analysis of Placental MSCs at passage 5; (d) ﬂowcytometric analysis of Placental MSCs at
passage 25; (e) RT-PCR analysis of placental MSCs (PhMSCs 020P3) for MHC class II antigens.6 Stem Cells International
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Figure 2: Pluripotency property of placental MSCs. (a) Oil red O staining (PhMSCsP5); (b) Von Kossa staining (PhMSCsP10); (c) “Falcon
25” static micromass cell culture system for chondrocyte diﬀerentiation; (d) saﬀranin O staining (PhMSCsP5); (e) hoechst 33342 staining
of myotubules; (f) tubular assay; (g) neural diﬀerentiation of placental MSCs (PhMSCsP20); (h) map2 staining (PhMSCs021P15); (i) NeuN
staining (PhMSCsP15); (j) GFAP staining (PhMSCs021P15); (k) Neural ﬁlament staining (PhMSCsP15); (l) Retinal cell diﬀerentiation of
placental MSCs (PhMSCsP9); (m) Pancreatic progenitor cell diﬀerentiation of placental MSCs (PhMSCsP9) (n) dithizone (DTZ) positive
pancreatic progenitor cells; (o) PCR analysis of ectodermal lineage (photoreceptor genes calbindin2 and recoverin) and endodermal lineage
(pancreatic amylase gene).
experiments after propidium iodide staining, we tested MSC
cell cycle status; Figure 3(a) shows during early and late
passaging there was not signiﬁcant change in the cell cycling
process. As detailed in Figure 3(b),k a r y o t y p e sw e r en o r m a l
46, XX in all test samples. Chromosome number was found
normal in all analyzed PD-MSC isolates (n = 8). Looking
at maternal origin, we found that PD-MSC isolates obtained
with our isolation procedure were always of maternal origin.
Also, it was important to document the apoptosis pattern of
the each passage proliferating MSC; Annexin-V and 7AAD
stainningdidnotshow(Figure 3(c))signiﬁcantchangeinthe
percentage apoptotic cells (∼5–7% cells).
3.4.PlacentalMSCsDisplaysHigherEndogenousGeneExpres-
sion of Oct4, Sox2 and Nanog Compared to BM-Derived MSC.
FACS analysis by Oct3/4, Stro-1 antibodies did show positive
reaction. Next, we wanted to analyze the pluripotency-
associated endogenous gene expression proﬁles of PD MSCs
and bone-marrow-derived MSC (BM-MSC). Figure 4 shows
data from comparative real-time qPCR, which revealed
higher expression levels of Oct4, Sox2, and nanog compared
to BM-MSC. Reports are also available of ﬂow cytometry
and immunocytochemistry, which revealed that PD-MSCs
were positive for stage-speciﬁc embryonic antigen SSEA-3
but negative for SSEA-4 [11].Stem Cells International 7
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Figure 3: Cell cycle karyotype analysis: (a) cell cycle pattern of early (passage 5) and late passage (passage 20). PD-MSC were analyzed
by FACS after propidim iodide staining. (b) Karyotype analysis was performed on early (passage 5) and late (passage25) passage MSC. (c)
Apoptosis analysis was done by FACS using Annexin V and 7AAD. (i). negative control. (ii) Total % apoptotic MSC cells (Passage 5). (iii) %
apoptotic cells (Passage 24) (iv).positive control.8 Stem Cells International
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Figure 4: Comparative analysis of pluripotency associated endoge-
nous gene expression between human marrow derived MSC
and human placenta-derived MSC. Oct4. Sox2, and nanog gene
expression proﬁles of bone-marrow-derived MSC and PDMSC
analyzed by real-time qPCR analysis; error bars represent SE in ﬁve
separate experiments.
3.5. In Vitro Tumor-Genesis Detection Assay. Placental MSCs
when subjected to soft agar assay did not yield tumoroids
even after 4 weeks of in vitro culture in soft agar assay
(Figure 5). However, HeLa cells began to form aggregates
within 7 days, and many bigger colonies were formed at the
e n do fd a y2 1( Figure 5).
4. Discussion
The human embryonic stem cells (ESCs) have the potential
to diﬀerentiate into all the three cell lineages [24]. However,
some of the practical and ethical concerns render them
in usable for day-to-day clinical applications. Nonetheless,
extra embryonic tissues can be eﬀectively used to isolate
pluripotent stem cells. Placenta is one of the extra embryonic
organs that has rich source of progenitor or stem cells
[25]. Placenta has two sides; one is foetal side consisting of
amnionandchorionandotheristhematernalsideconsisting
of deciduas [24]. Mesenchymal stem cells (MSCs) isolated
from maternal side of human term-placenta represent an
important cell type for stem cell research and clinical
therapy not only because of their ability to diﬀerentiate
into mesodermal lineage cells, such as osteocytes, chon-
drocytes, muscle, or endothelial cells [2], but also for
their remarkable translineage diﬀerentiation capabilities like
neuronal cells, retinal cells (ectodermal), and pancreatic beta
cells (endodermal lineage). In addition, they secrete large
amounts of proangiogenic and antiapoptotic cytokines [26]
and possess remarkable immunosuppressive properties [27].
MSCs have been derived from many diﬀerent organs and
tissues [28]. Evidence has emerged that diﬀerent parts of
human placenta, umbilical cords and amniotic membrane,
as well as umbilical cord blood harbor MSC [29–32]. These
tissues are normally discarded after birth, avoiding ethical
concerns [23] Mechanical, as well as enzymatic, methods
for MSC isolation from diﬀerent regions of human placenta
of diﬀerent gestational ages have been reported in literature
[29, 33–47]. Knowledge about vitality, average population
doubling time, stable karyotype, cell cycle and apoptosis
pattern, phenotype, and expandability of such placenta-
derived MSC isolates is a prerequisite for therapeutic appli-
cation; however, systematic investigations into reliability of
this MSC source and phenotypic stability did not get that
much attention. Furthermore, reports on placenta-derived
MSCs often lack information about the cell cycle, apopto-
sis pattern, progenitor-speciﬁc endogenous gene-expression
proﬁle, and karyotype of the cell isolates. In this paper, we
describe enzymatic fractionation of term-human placenta
that facilitates recovery of oligo-lineage, ﬁbroblast-like cells,
whichgenerallyaretermedasplacenta-derivedmesenchymal
stem cells (PDMSCs) with high ﬁdelity. As demonstrated
by cell cycle or apoptosis analysis of cells from early as
well as late passages; with average unaltered population
doubling time, PD-MSC did not shows signiﬁcant variations
in either cell cycle or apoptosis pattern. Also, genotypic
analyses of cell isolates from most of placental tissues were of
maternal, not fetal, origin. Our systematic characterization
of cell isolates from multiple cases showed that these cell
isolates reproducibly fulﬁll the general deﬁnition of MSCs
by both phenotypic and diﬀerentiation capabilities criteria.
[24]. We demonstrate that maternally derived PD-MSCs
can be greatly expanded, do not alter signiﬁcantly change
their cell cycle or apoptosis pattern, show pluripotency-
associated endogenous gene expression, and maintain their
diﬀerentiation capacity and stable phenotype displaying
unaltered kayotype up to passage 25–30 passages. In these
experiments, the placental MSCs were isolated from the
cotyledons present in the maternal side of the placenta.
Our method of cell isolation by way of sequential digestion
of the trophoblast cell layer with trypsin and following
digestion of remaining placental tissue with collagenase I
proved very eﬀective for obtaining PD MSCs. Outgrowth
of PD-MSCs from collagenase I digests was successful in
8 of 8 placental tissues and resulted in populations with
remarkably little scatter in their MSC proﬁles, between
subjects. As for propagation, we found out that PD-MSCs
mustbepropagatedinsubconﬂuentculturetomaintaintheir
MSC proﬁle, because conﬂuent culture led to gradual loss of
MSC identity. With proper subconﬂuent passage, PDMSCs
maintained their phenotypic MSC proﬁle up to 30 passages.
The ﬂow cytometry studies indicate there is signiﬁcant
similarity in surface marker characteristics from passage
1 till passage 30. Microscopic observations revealed that
placental MSCs proliferate rapidly till passage 30 without
compromising on the morphological features and quality
of the mesenchymal stem cell properties like cell cycle and
apoptosis pattern, pluripotency-associated endogenous gene
expression, and normal karyotype.
The characteristic data beyond passage 30 has not been
tested in this study. The MSCs had spindle shaped ﬁbroblast
morphology. The absence of HLA DRα and HLA DRβ1Stem Cells International 9
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Figure 5: Soft agar assay. (a)Placental MSCs day 7; (b) HeLa cells day 7; (c) Placental MSCs day 21; (d) HeLa cells ay21.
expression, analyzed from RT-PCR, results indicate that
placental MSCs could be eﬀectively used for both autologous
and allogenic transplantations. The rate of diﬀerentiation of
MSCs is much quicker, eﬃcient and scalable when compared
toEScells.Thesoftagarassayindicatesthatisolatedplacental
MSCs do not possess any malignant property. Several animal
aswellashumantrialshaveindicatedthatuseofMSCsunlike
ES cells does not lead to the formation of teratomas in vivo
[24]. In addition, usage of term placental MSCs has fewer
ethical concerns since they are isolated from foetal tissues
that anyway would have been discarded.
5. Conclusion
The human term-placenta is relatively easily available and
attracts less ethical concerns. Placental tissue constitutes
ar o b u s ts o u r c eo fM S C .I nt h i ss t u d y ,w ei n v e s t i g a t e d
several parameters, namely, (1) chromosome number, (2)
pluripotencyassociatedgeneexpression,(3)maternalorigin,
(4) sequential enzymatic digestion (trypsin followed by
collagenase) as methods of isolation, (5) cell propagation,
cell cycle, and apoptosis pattern, that are important for their
principal utility for cell-based therapy and could inﬂuence
their proliferative, as well as diﬀerentiation, capacities. Based
ontheresults,weconcludethattheabundanceofpluripotent
cells, rapid proliferation, stable karyotype, plasticity and
immunomodulatory property make placental MSCs ideal
choice for clinical and tissue engineering applications. Nev-
ertheless,themaindrawbackofusingMSCsisthat,apanelof
surface markers are required for characterization of isolated
MSCs for their homogeneity. Further, unlike the adult
MSCs, where signiﬁcant numbers of human clinical trials are
underway, use of placental MSCs in clinical applications is
relatively new. Additional studies are required to substantiate
the use of placental MSCs in medical applications.
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